US FDA warns Novo for second time about misleading drug advertising
Published on March 3, 2026.
The US Food and Drug Administration has warned Danish pharmaceutical company, Novo Nordisk, to stop running a consumer ad for its diabetes drug, Ozempic. This is the second time the FDA has warned Novo about misleading advertising. The warning was issued regarding a TV spot for Novo's drug, which also contains an anti-inflammatory drug.
Related Articles
Letters: Police are the wrong people for crisis intervention
Police are the wrong person for crisis intervention, advocating for a more holistic approach, while clinicians and social workers provide more effective, cost-effective responses to homelessness and mental health issues.
At 7, His Mom Noticed a Faint Discoloration. Months Later, He Was Diagnosed with a Rare Disorder That Slowly Ate His Skin (Exclusive)
Lukas Caldwell, now 22, was diagnosed with Parry-Romberg Syndrome, a rare autoimmune disorder that slowly eroded his face and body, leading to severe physical and social isolation.
Rapper Ice Spice reveals depression caused her weight loss, not Ozempic
Rapper Ice Spice attributed her weight loss to depression, rather than the controversial Ozempic treatment, and expressed her delight in being better-known.